Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw (#1323)

My legacy is going to be in affordable healthcare. I am willing to invest in developing that model and the policies around it.

$ 3 B
Biopharmaceuticals
India
F
73 Years

About Me

Kiran Mazumdar-Shaw, one of India's richest self-made women, founded biopharmaceutical firm Biocon, in 1978. The firm has successfully forayed into the lucrative U.S. market, and it also has one of Asia's largest insulin factories in Malaysia's Johor region. In December 2025, Biocon announced that it is buying the rest of privately held subsidiary Biocon Biologics to consolidate its biosimilars and generics drug businesses. The deal values Biocon Biologics at $5.5 billion, it said. Biocon Biologics acquired the biosimilars business of U.S. drugmaker Viatris in 2022 for $3.3 billion. In 2022, the Central Bureau of Investigation arrested a Biocon Biologics executive and four others in an alleged bribery case. The company denied any wrongdoing. Biocon-backed cancer therapy company Bicara Therapeutics raised $362 million in an IPO on the Nasdaq in September 2024.

Achievements

Career Highlights

A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Kiran Mazumdar-Shaw’s rise and global influence.

#1223 Billionaires (2026)
#83 Power Women (2025)
#93 India's Richest (2025)
#32 World's Richest Self-Made Women (2025)

Wealth Growth

Net Worth Growth Over Time

Tracking Kiran Mazumdar-Shaw’s net worth journey over the years, highlighting key growth phases and financial milestones.

Current Net Worth: $3.2B (May 4, 2026)